Could a brain chemical blocker ease social anxiety? new trial launches
NCT ID NCT07323784
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether a new drug called NTX-1472 can safely reduce symptoms of social anxiety disorder. About 100 adults will take either the drug or a placebo daily for 8 weeks. Researchers will measure changes in anxiety and avoidance using a standard scale, and track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NTX-1472 (a V1a receptor antagonist)
What this could lead to
If it works, this could point toward a new treatment option for social anxiety disorder that works differently from current medications.
What could go wrong
This is an early Phase 2 trial with only 100 participants, so results may not apply to everyone. The drug may not prove more effective than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOCIAL ANXIETY DISORDER (SAD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SOAR Clinical Study Site
RECRUITINGPheonix, Arizona, 85012, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SOAR Clinical Study Site
RECRUITINGEncino, California, 91316, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SOAR Clinical Study Site
RECRUITINGLos Angeles, California, 90025, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SOAR Clinical Study Site
RECRUITINGOceanside, California, 92056, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SOAR Clinical Study Site
RECRUITINGSan Jose, California, 95124, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SOAR Clinical Study Site
RECRUITINGJacksonville, Florida, 32256, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SOAR Clinical Study Site
RECRUITINGTampa, Florida, 33615, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SOAR Clinical Study Site
RECRUITINGBoston, Massachusetts, 02131, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SOAR Clinical Study Site
RECRUITINGBrooklyn, New York, 11229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SOAR Clinical Study Site
RECRUITINGMemphis, Tennessee, 38119, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SOAR Clinical Study Site
RECRUITINGAustin, Texas, 78737, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••